The addition of apixaban to antiplatelet therapy resulted in an increase in bleeding, but there was also an observed trend toward a reduction in clinically relevant ischemic events, a new dose-ranging study has shown.
Heartwire
Source: http://www.medscape.com/pharmacists?src=rss
Medscape Pharmacists Headlines